Chemokine/chemokine receptor interactions in extramedullary leukaemia of the skin in childhood AML: Differential roles for CCR2, CCR5, CXCR4 and CXCR7

Faaij, Claudia M.J.M.; Willemze, Annemiek; Révész, Tom; Balzarolo, Melania; Tensen, Cornelis P.; Hoogeboom, Manja; Vermeer, Maarten H.; Wering, Elisabeth van; Zwaan, C. Michel; Kaspers, Gertjan J. L.; Story, Colin; Halteren, Astrid G. S. van; Vossen, Jaak M.; Egeler, R. Maarten; Tol, Maarten J.D. van; Annels, Nicola

doi:10.1002/pbc.22500

Cited by 52 publications

(41 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Given that BM stromal cells are major producers of CXCL12, and CXCR4 expression is thought to be higher on BM-residing blasts than on circulating blasts, CXCR4/CXCL12 interactions are likely to facilitate the retention of blasts in the BM [18]. As ALL blasts are known to have high levels of CXCR4 and we also detected high levels of CXCR7, this receptor could possibly potentiate the homing and retention of these blasts in BM.…”

Section: Discussionmentioning

confidence: 62%

“…To date, most studies addressing the involvement of chemokines and their receptors in leukemic cell tropism have concentrated on the interaction of CXCL12 and its receptor CXCR4. Given that bone marrow (BM) stromal cells are major producers of CXCL12 [17], [18] and that CXCR4 expression is thought to be higher in BM-residing blasts than in circulating blasts, CXCL12/CXCR4 interactions are likely to facilitate the retention of blasts in the BM [18], [19]. Recently, another CXCL12-binding receptor has been identified.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

CXCR7 Is Highly Expressed in Acute Lymphoblastic Leukemia and Potentiates CXCR4 Response to CXCL12

et al. 2014

View full text Add to dashboard Cite

Recently, a novel CXCL12-binding receptor, has been identified. This CXCL12-binding receptor commonly known as CXCR7 (CXC chemokine receptor 7), has lately, based on a novel nomenclature, has received the name ACKR3 (atypical chemokine receptor 3). In this study, we aimed to investigate the expression of CXCR7 in leukemic cells, as well as its participation in CXCL12 response. Interesting, we clearly demonstrated that CXCR7 is highly expressed in acute lymphoid leukemic cells compared with myeloid or normal hematopoietic cells and that CXCR7 contributed to T-acute lymphoid leukemic cell migration induced by CXCL12. Moreover, we showed that the cellular location of CXCR7 varied among T-lymphoid cells and this finding may be related to their migration capacity. Finally, we hypothesized that CXCR7 potentiates CXCR4 response and may contribute to the maintenance of leukemia by initiating cell recruitment to bone marrow niches that were once occupied by normal hematopoietic stem cells.

show abstract

Section: Discussionmentioning

confidence: 62%

Section: Introductionmentioning

confidence: 99%

CXCR7 Is Highly Expressed in Acute Lymphoblastic Leukemia and Potentiates CXCR4 Response to CXCL12

et al. 2014

View full text Add to dashboard Cite

show abstract

“…This may represent a subclone of an original AML clone in cases of concurrent presentation or in the relapse situation. Faaij and colleagues compared the expression of chemokine receptors on AML blasts from the blood, BM and skin in pediatric AML patients with skin involvement to the expression on blasts from patients without EMD [Faaij et al 2010]. AML blasts isolated from the skin displayed a unique set of chemokine receptors including CCR5, CXCR4, CXCR7 and CX3CR1 compared with BM and blood blasts.…”

Section: Pathogenesis Of Extramedullary Diseasementioning

confidence: 99%

Myeloid sarcoma: current approach and therapeutic options

Avni

Koren‐Michowitz

2011

Therapeutic Advances in Hematology

214

289

View full text Add to dashboard Cite

Myeloid sarcoma is a rare disease that can present as an isolated extramedullary leukemic tumor, concurrently with or at relapse of acute myeloid leukemia. Owing to the rarity of this disorder, most of the literature comprises small retrospective studies and case reports. The aim of this review is to summarize the current published data regarding the clinical presentation, morphological, cytogenetic and molecular features, prognosis and treatment of myeloid sarcoma.

show abstract

“…These cytokinecytokine receptor interactions enable homing and survival of AML blasts in skin [ Figure 1]. [39] Expression of matrix metalloproteases may contribute to the increased incidence of EMI in some subtypes of AML. For example, in SHI-1 cells, a highly invasive human acute monocytic leukemia cell line, there is a high expression level of matrix metalloproteinase 2 (MMP-2), membranetype 1 MMP and tissue inhibitor of metalloproteinase, which facilitate cell invasion.…”

Section: Genetic and Molecular Features Of Extramedullary Infiltratiomentioning

confidence: 99%

Molecular and cellular aspects of extramedullary manifestations of acute myeloid leukemia

Mohammadi-Asl¹,

Khosravi²,

Shahjahani³

et al. 2015

J Cancer Metastasis Treat

View full text Add to dashboard Cite

The myeloid extramedullary tumor is a solid tumor formed by infiltration of immature myeloid cells in various tissues of the body. This tumor is also identified as chloroma or myeloid sarcoma (MS). MS is a manifestation of acute myeloid leukemia (AML) occurring at presentation or during treatment or relapse. MS is associated with multiple chromosomal abnormalities and molecular mutations since patients with these disorders bear a high potential for MS manifestation. There is a high incidence of extramedullary infiltration (EMI) in AML. AML patients with EMI have a worse prognosis than patients without it. Hematopoietic stem cells and leukemic stem cells reside in a special bone marrow microenvironment called niche, which is essential for their normal functions. Cancers are exploited dysfunctional cell-cell and matrix-cell interactions, which convert a normal niche into a neoplastic niche. This study summarizes the current knowledge on the molecular and cellular characteristics of AML with EMI and extramedullary niches in AML patients.

show abstract

Chemokine/chemokine receptor interactions in extramedullary leukaemia of the skin in childhood AML: Differential roles for CCR2, CCR5, CXCR4 and CXCR7

Cited by 52 publications

References 22 publications

CXCR7 Is Highly Expressed in Acute Lymphoblastic Leukemia and Potentiates CXCR4 Response to CXCL12

CXCR7 Is Highly Expressed in Acute Lymphoblastic Leukemia and Potentiates CXCR4 Response to CXCL12

Myeloid sarcoma: current approach and therapeutic options

Molecular and cellular aspects of extramedullary manifestations of acute myeloid leukemia

Contact Info

Product

Resources

About